Compare · ICLR vs SRNE
ICLR vs SRNE
Side-by-side comparison of ICON plc (ICLR) and Sorrento Therapeutics Inc. (SRNE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ICLR and SRNE operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- ICLR carries a market cap of $14.90B.
- ICLR has hit the wire 11 times in the past 4 weeks while SRNE has been quiet.
- ICLR has more recent analyst coverage (25 ratings vs 2 for SRNE).
- Company
- ICON plc
- Sorrento Therapeutics Inc.
- Price
- -
- -
- Market cap
- $14.90B
- -
- 1M return
- +11.24%
- -
- 1Y return
- +24.44%
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1998
- News (4w)
- 11
- 0
- Recent ratings
- 25
- 2
ICON plc
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services. The company's clinical development services also comprise medical imaging, biostatistics, medical affairs, pharmacovigilance, strategic regulatory, electronic endpoint adjudication, medical writing and publishing, interactive response technologies, functional solutions, strategic resourcing central laboratory, bioanalytical laboratory, biomarket development, strategy and analytics, late phase research, patient centered science, and medical device and diagnostics research services, as well as access, commercialization, and communication services, and research trials for us government agencies. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON has an agreement with Evergreen Therapeutics, Inc. to conduct Phase II clinical trial for COVID-19 drug candidate. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
Sorrento Therapeutics Inc.
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches; and Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host diseases. The company also develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. In addition, it engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain conditions. Additionally, the company has various collaborations with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 86 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patients with melanoma; and Karolinska Institutet. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.
Latest ICLR
- SEC Form 6-K filed by ICON plc
- ICON to Participate at Upcoming Investor Conferences
- Amendment: SEC Form SCHEDULE 13G/A filed by ICON plc
- ICON Launches FIRECREST AI-Directed Video Engine, Changing the Economics of Site Communications
- Director Murray Ciaran sold $709,956 worth of Ordinary Shares (3,452 units at $205.66), decreasing direct ownership by 17% to 17,000 units (SEC Form 4)
- Chief Executive Officer Balfe Barry Edward converted options into 9,662 units of Ordinary Shares and sold $1,069,441 worth of Ordinary Shares (5,175 units at $206.66), increasing direct ownership by 93% to 9,291 units (SEC Form 4) (tax liability)
- Chief Accounting Officer Lyons Emer converted options into 491 units of Ordinary Shares and sold $54,558 worth of Ordinary Shares (264 units at $206.66), increasing direct ownership by 23% to 1,217 units (SEC Form 4) (tax liability)
- Chief Financial Officer Clerkin Nigel Bernard John converted options into 2,778 units of Ordinary Shares and sold $307,503 worth of Ordinary Shares (1,488 units at $206.66), increasing direct ownership by 22% to 7,171 units (SEC Form 4) to cover withholding tax
- SEC Form 6-K filed by ICON plc
- SEC Form 6-K filed by ICON plc
Latest SRNE
- Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025
- Sorrento Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits
- Sorrento Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits
- Sorrento Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Sorrento Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Regulation FD Disclosure, Other Events
- Sorrento Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Sorrento Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- Sorrento Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-Q filed by Sorrento Therapeutics Inc.
- Sorrento Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits